Insider Buying: Immunocore Holdings plc (NASDAQ:IMCR) Director Buys $23,994,085.36 in Stock

Immunocore Holdings plc (NASDAQ:IMCR) Director Bros. Advisors Lp Baker purchased 807,338 shares of the business’s stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. The trade was a 60.40 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Immunocore Trading Down 2.0 %

NASDAQ:IMCR opened at $29.81 on Friday. The business’s 50-day moving average is $29.99 and its two-hundred day moving average is $31.16. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a 12 month low of $27.19 and a 12 month high of $66.00. The firm has a market capitalization of $1.49 billion, a PE ratio of -31.38 and a beta of 0.79.

Wall Street Analysts Forecast Growth

IMCR has been the subject of a number of research analyst reports. Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. Needham & Company LLC restated a “buy” rating and set a $71.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. Finally, HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.64.

Institutional Trading of Immunocore

Several large investors have recently modified their holdings of the business. Jefferies Financial Group Inc. acquired a new stake in shares of Immunocore during the fourth quarter valued at about $4,868,000. GF Fund Management CO. LTD. acquired a new position in Immunocore in the fourth quarter worth about $25,000. Woodline Partners LP grew its stake in Immunocore by 19.4% in the fourth quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock worth $9,678,000 after purchasing an additional 53,378 shares in the last quarter. Tang Capital Management LLC grew its stake in Immunocore by 40.7% in the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock worth $45,890,000 after purchasing an additional 450,000 shares in the last quarter. Finally, Tema Etfs LLC acquired a new position in Immunocore in the fourth quarter worth about $330,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.